What medication regimen is recommended for a 19-year-old female with ADHD, stress‑related disorder, anxiety, and possible borderline personality disorder who is impulsive, engages in reckless and self‑harm behaviors, is currently taking sertraline (Zoloft) and has previously discontinued cariprazine (Vraylar) due to sedation and aripiprazole (Abilify) due to weight gain?

Medication Management for Complex Presentation with ADHD, Anxiety, and Suspected BPD

For this 19-year-old with ADHD, anxiety, stress disorder, and suspected BPD presenting with severe impulsivity and self-harm, I recommend initiating a stimulant medication (methylphenidate or amphetamine) to address the ADHD while continuing sertraline, and avoiding atypical antipsychotics given her prior intolerances—with DBT as the primary treatment modality.

Rationale and Treatment Algorithm

Primary ADHD Treatment

The evidence strongly supports stimulants as first-line pharmacotherapy for ADHD, even in the presence of comorbid anxiety and impulsivity 1. Stimulants are effective in 70-80% of ADHD patients and demonstrate superior efficacy compared to non-stimulants 2. Critically, guidelines indicate that ADHD with comorbid anxiety disorders (including generalized anxiety, social phobia, and separation anxiety) may be treated with stimulants 3.

Specific recommendations:

• Methylphenidate is preferred for adolescents per recent meta-analyses 2
• Start with extended-release formulations for all-day coverage 1
• Begin at low doses and titrate slowly given anxiety comorbidity 4

Addressing the Substance Use Concern

Her underage drinking and legal violations create a clinical dilemma. However, non-stimulants like atomoxetine or guanfacine are specifically recommended as first-line options when substance use disorders are present 1. Given her current drinking is episodic rather than meeting criteria for substance use disorder, and considering the superior efficacy of stimulants, I would:

1. Conduct urine drug screening as recommended for adults with ADHD and substance use history 3
2. Monitor prescription refills closely for signs of misuse or diversion 5
3. Consider atomoxetine (60-100mg daily) as alternative if stimulant diversion risk is deemed too high 1
   • Atomoxetine is uncontrolled, provides around-the-clock effects, and has evidence for comorbid anxiety 1
   • Takes 6-12 weeks for full effect 1
   • Monitor for suicidality, particularly in first weeks 1

Managing Suspected BPD and Impulsivity

DBT is the evidence-based treatment for BPD and should be the primary intervention 2. Medication plays only an adjunctive role.

Regarding pharmacotherapy for BPD symptoms:

• No medications are FDA-approved for BPD 6
• Avoid polypharmacy and unsafe medications (those with overdose risk) 6
• The evidence for antipsychotics in BPD is limited and mixed 7, 8, 9

Given her prior medication failures:

• Vraylar (cariprazine): Caused sedation—this is a known adverse effect occurring in 4-7% of patients 10. Sedation is problematic for functioning.
• Abilify (aripiprazole): Caused weight gain—while aripiprazole generally has lower weight gain risk than olanzapine/quetiapine 11, it still occurs and is unacceptable to her.

I would NOT restart or switch to another atypical antipsychotic because:

1. Limited evidence supports their use in BPD 6
2. She's already failed two with intolerable side effects
3. Other options (quetiapine, olanzapine) have worse metabolic profiles 11
4. Lurasidone or ziprasidone are most weight-neutral 11 but lack BPD-specific evidence

Optimizing Current Sertraline

Sertraline is weight-neutral with long-term use 11 and appropriate for anxiety/depression. Ensure adequate dosing (typically 100-200mg for anxiety disorders) 12. The combination of stimulant medication plus sertraline for ADHD with comorbid anxiety has demonstrated efficacy 4.

Practical Implementation Strategy

Week 1-2:

• Continue sertraline at current dose
• Initiate methylphenidate extended-release (start 18mg daily) OR
• If substance concerns predominate, initiate atomoxetine 40mg daily

Week 2-4:

• Titrate methylphenidate by 9-18mg increments weekly to effect (typical range 36-72mg) 1
• OR titrate atomoxetine to 80-100mg daily over 2-4 weeks 1
• Monitor: blood pressure, pulse, appetite, sleep, mood, anxiety symptoms
• Assess for stimulant diversion/misuse

Week 4-8:

• Continue DBT intensively (this is the primary treatment)
• Optimize ADHD medication dosing
• Monitor impulsivity, self-harm behaviors, legal compliance

Week 8-12:

• Reassess all symptoms using standardized scales
• If impulsivity/aggression remains severe despite optimized ADHD treatment and DBT, consider adding low-dose mood stabilizer (divalproex 250mg BID, titrate to level 40-90 mcg/mL) 13

Critical Caveats

Avoid these common pitfalls:

1. Don't withhold stimulants solely due to anxiety—evidence shows they can improve both ADHD and anxiety symptoms 3, 4
2. Don't add benzodiazepines—risk of tolerance, addiction, and paradoxical agitation in 10% of patients 13
3. Don't restart antipsychotics without clear psychotic symptoms—limited BPD evidence and she's failed two already
4. Don't use bupropion—while weight-neutral 11, it's activating and can exacerbate anxiety 11, and she already has significant anxiety

Monitor closely for:

• Suicidal ideation (black box warning for atomoxetine and all antidepressants in young adults) 1, 12
• Stimulant diversion given legal history 5
• Cardiovascular effects (BP, pulse) with stimulants 1
• Worsening impulsivity or mood instability

The legal situation warrants psychiatric documentation that treatment is being optimized and compliance monitored, as this may be relevant to her legal proceedings.